Outcomes according to MN1, expression in older CN-AML within the ELN genetic groups
| End point . | All . | Low MN1 . | High MN1 . | P* . | OR/HR (95% CI) . |
|---|---|---|---|---|---|
| ELN Favorable group | n = 66 | n = 40 | n = 26 | ||
| CR, no. (%) | 51 (77) | 33 (83) | 18 (69) | .24 | 2.10 (0.65, 6.72) |
| DFS | .84 | ||||
| Median, y | 0.9 | 1.0 | 0.7 | 1.07 (0.56, 2.03) | |
| Disease-free at 3 y, % (95% CI) | 22 (12-34) | 21 (9-36) | 22 (7-43) | ||
| OS | .81 | 0.94 (0.54, 1.61) | |||
| Median, y | 1.5 | 1.5 | 1.4 | ||
| Alive at 3 y, % (95% CI) | 29 (18-40) | 32 (19-47) | 23 (9-40) | ||
| EFS | .69 | 0.90 (0.53, 1.53) | |||
| Median, y | 0.8 | 0.9 | 0.6 | ||
| Event-free at 3 y, % (95% CI) | 17 (9-27) | 18 (8-31) | 15 (5-31) | ||
| ELN Intermediate-I group | n = 74 | n = 30 | n = 44 | ||
| CR, no. (%) | 42 (57) | 23 (77) | 19 (43) | .008 | 4.32 (1.54, 12.17) |
| DFS | .15 | 0.63 (0.33, 1.20) | |||
| Median, y | 0.5 | 0.6 | 0.5 | ||
| Disease-free at 3 y, % (95% CI) | 7(2-17) | 13 (3-30) | 0 (NA) | ||
| OS | .05 | 0.61 (0.38, 1.00) | |||
| Median, y | 0.7 | 0.9 | 0.7 | ||
| Alive at 3 y, % (95% CI) | 5 (2-12) | 10 (3-24) | 2 (.1-10) | ||
| EFS | .003 | 0.49 (0.30, 0.80) | |||
| Median, y | 0.3 | 0.6 | 0.2 | ||
| Event-free at 3 y, % (95% CI) | 4 (1-10) | 10 (3-24) | 0 (NA) |
| End point . | All . | Low MN1 . | High MN1 . | P* . | OR/HR (95% CI) . |
|---|---|---|---|---|---|
| ELN Favorable group | n = 66 | n = 40 | n = 26 | ||
| CR, no. (%) | 51 (77) | 33 (83) | 18 (69) | .24 | 2.10 (0.65, 6.72) |
| DFS | .84 | ||||
| Median, y | 0.9 | 1.0 | 0.7 | 1.07 (0.56, 2.03) | |
| Disease-free at 3 y, % (95% CI) | 22 (12-34) | 21 (9-36) | 22 (7-43) | ||
| OS | .81 | 0.94 (0.54, 1.61) | |||
| Median, y | 1.5 | 1.5 | 1.4 | ||
| Alive at 3 y, % (95% CI) | 29 (18-40) | 32 (19-47) | 23 (9-40) | ||
| EFS | .69 | 0.90 (0.53, 1.53) | |||
| Median, y | 0.8 | 0.9 | 0.6 | ||
| Event-free at 3 y, % (95% CI) | 17 (9-27) | 18 (8-31) | 15 (5-31) | ||
| ELN Intermediate-I group | n = 74 | n = 30 | n = 44 | ||
| CR, no. (%) | 42 (57) | 23 (77) | 19 (43) | .008 | 4.32 (1.54, 12.17) |
| DFS | .15 | 0.63 (0.33, 1.20) | |||
| Median, y | 0.5 | 0.6 | 0.5 | ||
| Disease-free at 3 y, % (95% CI) | 7(2-17) | 13 (3-30) | 0 (NA) | ||
| OS | .05 | 0.61 (0.38, 1.00) | |||
| Median, y | 0.7 | 0.9 | 0.7 | ||
| Alive at 3 y, % (95% CI) | 5 (2-12) | 10 (3-24) | 2 (.1-10) | ||
| EFS | .003 | 0.49 (0.30, 0.80) | |||
| Median, y | 0.3 | 0.6 | 0.2 | ||
| Event-free at 3 y, % (95% CI) | 4 (1-10) | 10 (3-24) | 0 (NA) |
OR indicates the odds of achieving a CR for low MN1 vs high MN1 expressers; HR, the hazard of having an event for low MN1 vs high MN1 expressers; CI, confidence interval; and NA, not applicable (CI could not be attained).
P values for categorical variables are from Fisher exact test. P values for time-to-event variables are from the log-rank test (OS, DFS, and EFS).